-
1 Comment
Avicanna Inc is currently in a long term downtrend where the price is trading 0.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
Avicanna Inc's total revenue rose by 17742.5% to $882K since the same quarter in the previous year.
Its net income has dropped by 10.1% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.3% to $-6M since the same quarter in the previous year.
Based on the above factors, Avicanna Inc gets an overall score of 3/5.
Exchange | TO |
---|---|
CurrencyCode | CAD |
ISIN | CA05368K1003 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Beta | 0.27 |
---|---|
Market Cap | 28M |
PE Ratio | None |
Target Price | 0.7 |
Dividend Yield | None |
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. The company commercializes approximately thirty proprietary evidence-based finished products. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, and educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens, as well as collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AVCN.TO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025